Trial Receives FDA Green Light to Proceed Evaluating EVX-01, Keytruda Combo in Metastatic Melanoma
Source: Cure Today, January 2023
A phase 2 trial evaluating EVX-01 plus Keytruda (pembrolizumab) in patients with metastatic melanoma may continue, the FDA said.
Evaxion Biotech, a Denmark-based biotechnology company, may proceed with a phase 2b clinical trial evaluating EVX-01 in combination with Keytruda (pembrolizumab) for the treatment of patients with metastatic melanoma, according to a press release from the company.
The approval from the Food and Drug Administration (FDA) to continue the trial comes after the company submitted an Investigational New Drug Application and Fast Track designation application to the FDA for the trial.